Ttafasitamab plus lenalidomide (TAFA+LEN) versus pola-BR, r2, and CAR-T in non-transplant eligible (NTE) relapsed/refractory (r/r) DLBCL: A post hoc analysis of the RE-MIND2 study comparing multiple cohort-balancing approaches Meeting Abstract
| Authors: | Córdoba, R.; Zinzani, P. L.; Joffe, E.; Yoon, D. H.; Peters, A.; Waltl, E. E.; Alvero, C.; Sabatelli, L.; Salles, G.; Nowakowski, G. S. |
| Abstract Title: | Ttafasitamab plus lenalidomide (TAFA+LEN) versus pola-BR, r2, and CAR-T in non-transplant eligible (NTE) relapsed/refractory (r/r) DLBCL: A post hoc analysis of the RE-MIND2 study comparing multiple cohort-balancing approaches |
| Meeting Title: | ISPOR Europe 2022 |
| Journal Title: | Value in Health |
| Volume: | 25 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Nov 6-9 |
| Meeting Location: | Vienna, Italy |
| ISSN: | 1098-3015 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2022-12-01 |
| Start Page: | S30 |
| Language: | English |
| ACCESSION: | WOS:000897594900128 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jval.2022.09.146 |
| Notes: | Meeting Abstract: CO67 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work